Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P14324
UPID:
FPPS_HUMAN
Alternative names:
(2E,6E)-farnesyl diphosphate synthase; Dimethylallyltranstransferase; Farnesyl diphosphate synthase; Geranyltranstransferase
Alternative UPACC:
P14324; D3DV91; E9PCI9; Q96G29
Background:
Farnesyl pyrophosphate synthase, also known as (2E,6E)-farnesyl diphosphate synthase, plays a pivotal role in isoprenoid biosynthesis. This enzyme catalyzes the formation of farnesyl diphosphate (FPP), a precursor for vital metabolites including sterols, dolichols, carotenoids, and ubiquinones, essential for cellular function and integrity. FPP is also a substrate for protein modifications such as farnesylation and geranylgeranylation, crucial for protein localization and function.
Therapeutic significance:
The enzyme's link to Porokeratosis 9, a disorder characterized by abnormal skin keratinization leading to neoplasms, underscores its therapeutic significance. Targeting Farnesyl pyrophosphate synthase could offer novel treatment avenues for skin disorders and potentially inhibit the progression to cutaneous neoplasms.